Expressive

rs11173201 - SLC16A7 - Y_RNA

Magnitude 2.2 · 1 study on file

Reported associations

  • Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. - Nature genetics (2022) · Watanabe K, Jansen PR, Savage JE, Nandakumar P, Wang X, Hinds DA, Gelernter J, Levey DF, Polimanti R, Stein MB, Van Someren EJW, Smit AB, Posthuma D · PubMed 35835914

    Insomnia is a heritable, highly prevalent sleep disorder for which no sufficient treatment currently exists. Previous genome-wide association studies with up to 1.3 million subjects identified over 200 associated loci. This extreme polygenicity suggested that many more loci remain to be discovered. The current study almost doubled the sample size to 593,724 cases and 1,771,286 controls, thereby increasing statistical power, and identified 554 risk loci (including 364 novel loci). To capitalize on this large number of loci, we propose a novel strategy to prioritize genes using external biological resources and functional interactions between genes across risk loci. Of all 3,898 genes naively implicated from the risk loci, we prioritize 289 and find brain-tissue expression spec

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • sleep disorder screening and CBT-I Moderate

    SLC16A7 variant increases insomnia risk; professional assessment and cognitive-behavioral therapy for insomnia are first-line treatments

    request sleep assessment and CBT-I referral

Exercise

  • aerobic exercise for sleep optimization Moderate

    Regular aerobic activity improves sleep architecture and quality, offsetting SLC16A7-associated insomnia risk

    150 minutes moderate aerobic activity weekly, completed before 4 PM

Lifestyle

  • caffeine in afternoon and evening Moderate

    Caffeine delays sleep onset and reduces sleep quality; critical with SLC16A7-mediated insomnia susceptibility

    eliminate caffeine after 2 PM

  • consistent sleep schedule Moderate

    Regular bedtime and wake time regulate circadian rhythm and reduce insomnia severity, particularly beneficial for SLC16A7-mediated risk

    maintain consistent bedtime/wake time, target 7-9 hours nightly

Screening

  • sleep quality and duration tracking Moderate

    SLC16A7 variant increases insomnia risk; regular monitoring helps identify sleep deterioration early

    track sleep duration and quality daily for 2 weeks, then weekly